-

03:23:44 PM

TCON Stock News

TCON - TRACON Pharmaceuticals Inc

09/14/22 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

very positive

09/07/22 8:00 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel

RHEA-AI

neutral

08/29/22 8:00 PM

Nasdaq : TCON

fda approvallow float

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Biocytogen Pharmaceuticals Co., Ltd. and TRACON Pharmaceuticals, Inc., today jointly announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for the initiation of a Phase 1/ 2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients,...

RHEA-AI

very positive

08/29/22 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

08/10/22 4:02 PM

Nasdaq : TCON

earningslow float

TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

08/10/22 8:00 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics

RHEA-AI

neutral

07/27/22 8:05 AM

Nasdaq : TCON

conferencesearningslow float

TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life

RHEA-AI

neutral

07/26/22 8:05 AM

Nasdaq : TCON

low float

TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other

RHEA-AI

neutral

06/02/22 8:05 AM

Nasdaq : TCON

conferenceslow float

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

TCON Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.traconpharma.com
Security nameTRACON Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees18
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About TRACON Pharmaceuticals Inc

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company's clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.